What do you think of Imclone and their C225 anti-egf MAb for Head & Neck cancer. They are trading at close to a $2B cap. They have held steady in this storm with a product in pivotal trials but still are much farther away from approval than Campath.
What makes them resistant to this biotech plague going on?
Before your post, I was going to say "No posts today -- kinda says it all!" My second of three orders ($16, 15 and 14) filled today. Perhaps the third will go through tomorrow?
What a dismal yet opportunistic time we're in right now. I referred to the 8/30-9/1/1998 sessions in an earlier post. I believe the NASDAQ was somewhere around 1748 or 175 points below where it closed today. Only another 9% to go to reach that level. I think that would be too much for the money managers sitting on tons of cash to pass up, even considering all of the doom and gloom forecasts being bandied about.
This could well mark an historic buying opportunity for those who can and do make the trades. Although, I would look for stocks like MLNM and IDPH to lead the biotech group higher, leaving ones like ILXO and TXB to bring up the rear later in the year...